SAFINAMIDE MEDICIANZ safinamide (as mesilate) 50 mg tablet bottle
Analogs of SAFINAMIDE MEDICIANZ safinamide (as mesilate) 50 mg tablet bottle
Find cheaper analogs and generic equivalents for SAFINAMIDE MEDICIANZ safinamide (as mesilate) 50 mg tablet bottle.
Wirkstoff: safinamide mesilate
Produktübersicht
About SAFINAMIDE MEDICIANZ safinamide (as mesilate)
SAFINAMIDE MEDICIANZ safinamide (as mesilate) is a medication containing the active ingredient safinamide mesilate, classified as Reversible monoamine oxidase B inhibitor. Safinamide, sold under the brand name Xadago among others, is a medication used as treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.
Key Benefits & Uses
- Used for: Safinamide, sold under the brand name Xadago among others, is a medication used as treatment for Parkinson's disease with "off" episodes
- Used for: it has multiple modes of action, including the inhibition of monoamine oxidase B
- Use only as directed on the product label or by a healthcare professional.
Active Ingredient & Action
safinamide mesilate, the active ingredient in SAFINAMIDE MEDICIANZ safinamide (as mesilate), belongs to the Reversible monoamine oxidase B inhibitor class. Its clinical use follows the authorised labelling for safinamide mesilate-containing medicines. Inactive ingredients: not listed in source data.
Important Notes
Always read and follow the label instructions carefully before taking SAFINAMIDE MEDICIANZ safinamide (as mesilate). If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use SAFINAMIDE MEDICIANZ safinamide (as mesilate) for extended periods without medical advice.
Find in Pharmacies
Compare local prices and distance for SAFINAMIDE MEDICIANZ safinamide (as mesilate) 50 mg tablet bottle.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.